Author(s): Zhang JJ, Sun WJ, Huang ZX, Chen SL, Zhong YP,
Abstract Share this page
Abstract BACKGROUND: We intended to investigate the long-term clinical characteristics, responses to therapy and survival in patients with lightchain multiple myeloma (MM). METHODS: Ninety-six patients were enrolled into the study. There were 42 κ-chain MM patients and 54 λ-chain MM patients. All the patients werestage III in the Durie-Salmonstaging system. Among them, 66 patients received Velcade (bortezomib) treatment and the other 30 did not. RESULTS: The main symptoms of these patients included bone pain (77.1\%), weakness and fatigue (12.5\%), foamy urine (8.3\%) and extramedullaryplasmocytomas (33.3\%). The overall response rate (ORR) was 95.5\% in patients treated with Velcade and 60\%in the patients without. The median survival times were 23 months in patients treated with Velcade and 12 months in patients without. The median time of progression-free survival (PFS) was nine months in patients treated with Velcade and five months in patients without. The one-year PFS and two-year PFS were 37\% and 25\%, 27\% and 9\% for patients treated with Velcade, or without, respectively. The three-year overall survival (OS) and five-year OS were 33\% and 24\%, 28\% and 9\% for patients treated with Velcade, or without, respectively. There was no significance in OS between the two groups (P = 0.335). But there was significant difference in PFS between the two groups (P = 0.036). CONCLUSIONS: Our long-term study demonstrated that patients with lightchain myeloma appeared to have more aggressive disease courses and poor outcomes, which could be improved by treatment with Velcade.
This article was published in World J Surg Oncol
and referenced in Journal of Antivirals & Antiretrovirals